TY - JOUR T1 - Therapeutic Anticoagulation Is Associated with Decreased Mortality in Mechanically Ventilated COVID-19 Patients JF - medRxiv DO - 10.1101/2020.05.30.20117929 SP - 2020.05.30.20117929 AU - Muoi A. Trinh AU - Daniel R. Chang AU - Usha S. Govindarajulu AU - Erica Kane AU - Valentin Fuster AU - Roopa Kohli-Seth AU - Sanam Ahmed AU - Matthew A Levin AU - Martin D. Chen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/03/2020.05.30.20117929.abstract N2 - Objective To evaluate differences in morbidity and mortality among mechanically ventilated patients with COVID-19 treated with therapeutic versus prophylactic anticoagulation.Methods We performed a retrospective review of 245 COVID-19 positive patients admitted to the ICU requiring mechanical ventilation from March 1, 2020 through April 11, 2020 at Mount Sinai Hospital. Patients either received therapeutic anticoagulation for a minimum of 5 days or prophylactic dose anticoagulation. Morbidity and mortality data were analyzed.Results Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course. A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% Cl (0.10, 0.46), p < 0.001]. Bleeding complications were similar between both groups. A 26.7% [95% Cl (1.16, 1.39), p< 0.001] excess mortality was found for each 1 mg/dL rise in serum creatinine over a 21-day period.Conclusions Therapeutic anticoagulation is associated with a survival advantage among patients with COVID-19 who require mechanical ventilation in the ICU.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRetrospective Observational StudyFunding StatementInternal/Departmental FundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Program for the Protection of Human Subjects, Icahn School of Medicine at Mount Sinai, New York, NY 10029All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA de-identified data set may be made available upon request, for reproducibility or collaborative purposes only, subject to approval by the Mount Sinai Data Use Committee. ER -